



Ref. No.: EIKO/BSE/2023-24/06

Dated: 09.05.2023

To,
Corporate Services Department,
BSE Limited, P J Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.
BSE Scrip Code: EIKO 540204

Sub: Outcome of the Board Meeting

Ref: Eiko Lifesciences Limited

BSE Scrip Code: EIKO 540204

Dear Sir,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), We would like to inform you that at the meeting of the Board of Directors of the Company held on Tuesday, May 09, 2023, which commenced at 4.00 p.m. and ended at 4.55 p.m. have interalia, approved and taken on record the following:

1. Audited Financial Results of the Company for the Quarter and year ended 31st March 2023 along with Auditor’s Report duly signed by the Auditor of the Company. A Copy of the same is enclosed herewith as **Annexure I**.
2. Declaration from Chief Financial Officer regarding unmodified opinion in the audit Report issued by the Thanawala & Company, Statutory auditor of the Company on Financial results. A Copy of the same is enclosed herewith as **Annexure II**
3. Appointment of M/s Shравan Gupta & Associates, Practicing Company Secretary, as Secretarial Auditor for financial year 2023-24. The details of Secretarial Auditor as required under Regulation 30 of the SEBI (LODR), Regulation, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015 are mentioned in annexure attached as **Annexure – III**



4. Appointment of M/s NP Rajput & Co., Chartered accountant, as Internal Auditor for financial year 2023-24. The details of Internal Auditor as required under Regulation 30 of the SEBI (LODR), Regulation, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015 are mentioned in annexure attached as **Annexure – IV**

For EIKO LIFESCIENCES LIMITED

Avi Mundecha
Company Secretary
ACS-65529

AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED 31ST MARCH 2023

(₹ in Lakhs, except per share data)

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		(Audited)	(Un-Audited)	(Audited)	(Audited)	(Audited)
1	Revenue from operations	659.44	437.58	529.19	1,832.14	2,543.24
	Other income	20.81	18.61	20.54	85.48	65.28
	Total revenue	680.25	456.18	549.72	1,917.62	2,608.52
2	Expenses					
	Cost of material consumed	593.31	233.15	413.72	1,366.49	2,504.78
	Changes in inventories of finished stock and work-in-progress	0.65	150.22	52.82	242.85	(246.62)
	Employee benefits expense	6.34	7.85	7.01	28.71	27.70
	Depreciation and amortization expense	15.95	15.83	15.64	63.28	56.24
	Finance Cost	3.46	1.31	10.63	15.03	46.42
	Other expenses	22.76	13.90	30.71	98.64	125.80
	Total expenses	642.46	422.25	530.52	1,815.00	2,514.32
	Profit/(Loss) from ordinary activities before tax	37.79	33.93	19.20	102.62	94.20
3	Tax expense:					
4	(1) Current tax	4.83	0.01	-	4.84	-
	(2) Earlier year's Tax	-	-	-	-	0.25
	(4) Deferred tax	4.67	8.53	4.51	20.91	23.38
	Profit/(Loss) from ordinary activities after tax	28.29	25.39	14.69	76.88	70.57
5	Other Comprehensive Income (OCI)					
6	<u>Item that will not be reclassified to profit or loss</u>					
	Gain/(Loss) on recognised on fair valuation of Financial Assets	-	-	2.47	3.21	(2.19)
	Income tax relating to these items	-	-	(0.62)	(0.81)	0.55
	Total Other Comprehensive Income (OCI)	-	-	1.85	2.40	(1.64)
	Profit/(Loss) for the Period	28.29	25.39	16.54	79.28	68.94
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	831.63	831.63	831.63	831.63	831.63
7	Earnings Per Share (EPS) (Not annualised)					
	(1) Basic	0.34	0.31	0.18	0.92	0.90
	(2) Diluted	0.34	0.31	0.18	0.92	0.90

For Eiko LifeSciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
Din: 00061346





AUDITED BALANCE SHEET FOR PERIOD ENDED 31ST MARCH 2023

(₹ in Lakhs)

Particulars	As at 31-03-2023	As at 31-03-2022
ASSETS		
Non-current assets		
Property, Plant and Equipment	1,388.11	1,428.92
Financial Assets		
Investments	5.35	20.02
Loans	668.44	230.26
Other Financial Assets	112.26	566.65
	2,174.16	2,245.85
Current assets		
Inventories	90.76	545.75
Financial Assets		
Trade Receivables	710.56	456.23
Cash and cash equivalents	61.24	21.73
Other Current Assets	67.56	219.81
	930.12	1,243.53
TOTAL ASSET	3,104.28	3,489.37
EQUITY AND LIABILITIES		
EQUITY		
Equity Share capital	831.63	831.63
Other Equity	2,110.60	2,031.32
	2,942.23	2,862.95
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
Non-Current Borrowings	-	5.36
Deferred Tax Liabilities	42.18	20.47
	42.18	25.83
Current liabilities		
Financial Liabilities		
1. Current Borrowing	-	449.96
2. Trade Payables	104.53	134.85
3. Other Financial Liabilities	5.36	7.45
Provisions	4.55	3.35
Other current Liability	5.43	4.99
	119.87	600.60
TOTAL LIABILITIES	3,104.28	3,489.37

For Eiko LifeSciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
Din: 00061346



AUDITED STATEMENT OF CASH FLOWS FOR PERIOD ENDED 31ST MARCH 2023

(₹ in Lakhs)

Particulars	Year ended 31.03.2023	Year ended 31.03.2022
<u>A. CASH FLOW FROM OPERATING ACTIVITIES</u>		
Net (loss) / profit before tax	102.62	94.20
Adjustments for		
Depreciation and Amortisation Expense	63.28	56.24
Profit on Sales of Investments	(3.15)	-
Dividend Income	(0.00)	(0.40)
Finance Costs	15.03	46.42
Interest Income classified as investing cash flow	(72.71)	(63.84)
Operating profit before working capital changes	105.07	132.63
Working capital adjustments: -		
Increase / (Decrease) in Trade and Other Payables	(30.31)	(54.65)
Increase / (Decrease) in Provisions	1.20	(26.64)
Increase / (Decrease) in Other current Liabilities	0.44	3.26
Increase / (Decrease) in Other Financial Liabilities	(2.09)	0.65
(Increase) / Decrease in Inventories	454.99	(539.40)
(Increase) / Decrease in Trade Receivables	(254.33)	(114.76)
(Increase) / Decrease in Other Current Assets	139.88	(152.71)
Cash generated from / (used in) operations	414.85	(751.63)
Direct taxes paid (Net of Refunds)	7.53	(21.11)
Net cash (used in) / from generated from operating activities	422.38	(772.73)
<u>B. CASH FLOW FROM INVESTING ACTIVITIES</u>		
Sale/(Purchase) of Investments	21.02	(0.26)
Sale/(Purchase) of Fixed Assets	(22.47)	(15.46)
Proceed from Deposit	16.21	10.72
Interest Income	72.71	63.84
Dividend received	0.00	0.40
Net cash (used in) / generated from investing activities	87.47	59.24
<u>C. CASH FLOW FROM FINANCING ACTIVITIES</u>		
Proceeds from issue of shares	-	94.99
Interest paid	(15.03)	(46.42)
Proceeds /(Repayment) from borrowings	(455.32)	279.45
Net cash (used in) / from financing activities	(470.35)	328.02
Net decrease in cash and cash equivalents (A+B+C)	39.51	(385.47)
Cash and cash equivalents at the beginning of the year	21.73	407.20
Cash and cash equivalents at the end of the year	61.24	21.73

For Eiko LifeSciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
Din: 00061346





Notes:

1. The figures for the corresponding previous quarter/year have been regrouped/reclassified wherever necessary, to make them comparable. The figures for the quarter ended March 31, 2023, are balancing figures between the audited figures of the full financial year and the limited reviewed year-to date figures upto the third quarter of the financial year.
2. These financial results have been compiled from the related interim financial information which has been prepared in accordance with the recognition and measurement principles of the Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. These financial results have been prepared pursuant to the requirements of Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and comply with the disclosure requirements contained therein. The financial results for the year ended March 31, 2023, have been audited by the statutory auditors of the Company.
3. The above Audited Financial Results for the quarter and year ended 31st March 2023 have been reviewed and recommended by Audit Committee and have been approved by the Board of Directors at its Meeting held on Tuesday, 9th May 2023. The statutory auditors of the Company have issued audit reports with unmodified opinion on the above results.
4. The Company has a single business segment, namely "Speciality & Fine Chemicals" therefore in the context of Ind As 108, disclosure of segment information is not applicable.

For Eiko LifeSciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
Din: 00061346



Date: 9th May 2023
Place: Thane



INDEPENDENT AUDITOR'S REPORT
To the Board of Directors of EIKO LIFESCIENCES LIMITED
Report on the Audit of Financial Results

Opinion

We have audited the annual financial results of **EIKO LIFESCIENCES LIMITED** (hereinafter referred to as the 'Company') for the year ended March 31, 2023 and the Balance Sheet and the Statement of Cash Flows as at and for the year ended on that date, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial results:

- i. are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net loss and other comprehensive income and other financial information of the Company for the year ended March 31, 2023 and the balance sheet and the statement of cash flows as at and for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India.' Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management and Board of Directors' Responsibilities for the Financial Results

These financial results have been prepared based on the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the balance sheet and the statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards

prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the financial results by the Directors of the Company, as aforesaid.

In preparing the financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- i. Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ii. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- iii. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- iv. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- v. Evaluate the overall presentation, structure and content of the standalone financial results including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- vi. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The statement includes the results for the quarter ended March 31, 2023, being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2023, and the published unaudited year-to-date figures up to the third quarter of the current financial year, which are subjected to a limited review by us, as required under the Listing Regulations.

For Thanawala & Company

Chartered Accountants

Firm Reg. No.: 110948W

CA Vijay Thanawala

Proprietor

Membership No.: 015632



Place: Thane

Date: 9th May 2023

UDIN: 23015632BGWOGF4564



Annexure II

To,
Corporate Services Department,
BSE Limited, P J Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.
BSE Scrip Code: EIKO 540204

Ref: Eiko Lifesciences Limited
BSE Scrip Code: EIKO 540204

Dear Sir,

Subject: Declaration in respect of Unmodified Opinion on Audited Financial Results of the Company for the Financial Year ended March 31, 2023.

I, Jaid Kojar, Chief Financial Officer of Eiko Lifesciences Limited hereby declare that the Company's Statutory Auditor M/s Thanawala & Co Chartered Accountants, has submitted an unmodified opinion/unqualified opinion on the Audited Financial Results for the year ended 31st March 2023.

This declaration is given in compliance with Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to take the above on your records and acknowledge receipt.

Thanking you,

For Eiko Lifesciences Limited

Jaid Kojar,
Chief Financial Officer

Date: 09.05.2023

Place: Thane